Show Summary Details
Page of

Antiretroviral Nanotherapies 

Antiretroviral Nanotherapies
Antiretroviral Nanotherapies

Madhavan P. N. Nair

and Zainulabedin M. Saiyed

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 14 July 2020

Although highly active anti-retroviral therapy has significantly reduced the severity of HIV disease, complete eradication of virus from hard-to-access reservoirs in the HIV-infected patient remains a major challenge. The central nervous system, protected by its blood-brain barrier (BBB), represents one of the major anatomical reservoirs for HIV-1. Nanotechnology-based drug delivery systems have shown tremendous potential for penetrating the BBB and targeting antiretroviral drugs to the brain. This review highlights selected nanotechnology-based drug delivery systems that hold the potential for future effective treatment of HIV-associated neurocognitive disorders. Results from our laboratory on the use of magnetically-guided nanocarrier-based drug delivery systems for targeting active forms of antiretroviral drugs to the brain are discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.